Overview

This bill directs the Federal Trade Commission to investigate, report on, and ultimately regulate unfair or deceptive advertising and marketing practices in the preterm infant formula industry. The legislation responds to concerns that manufacturers and importers of preterm infant formula may be engaging in marketing practices that obscure or omit critical health risk information from consumers — specifically parents and caregivers of premature infants who are among the most medically vulnerable population. The bill establishes a two-phase regulatory approach: first requiring the FTC to conduct a thorough investigation and deliver findings to Congress, and then mandating the promulgation of enforceable regulations based on those findings. The overarching objective is to ensure that families making life-critical nutritional decisions for preterm infants have access to complete, accurate, and non-deceptive information about the products they are using.

Key Points

• Directs the FTC to investigate deceptive advertising and marketing of preterm infant formula
• Requires a congressional report with legislative and administrative recommendations within one year of enactment
• Mandates FTC rulemaking to prohibit deceptive practices within 18 months of the report's submission
• Focuses specifically on marketing materials that omit health risk labeling information
• Establishes enforcement through the existing Federal Trade Commission Act framework

Core Provisions

The bill's operative provisions are contained in Section 3, which creates two distinct but sequential obligations for the FTC. Under §3(a), the Commission must conduct a comprehensive investigation into unfair or deceptive acts or practices prevalent in the advertising and marketing of preterm infant formula and submit a report to Congress that includes both findings and recommendations for legislative or administrative action. This investigation phase must be completed within one year of enactment. Under §3(b), the FTC must then promulgate regulations — using notice-and-comment rulemaking under 5 U.S.C. § 553 — that specifically prohibit unfair or deceptive acts or practices in this space. These regulations must address, at minimum, advertising or marketing materials that exclude labeling information about potential health risks associated with the consumption of preterm infant formula and fortifiers, as defined under the Federal Food, Drug, and Cosmetic Act at 21 U.S.C. § 350a(h)(1). The rulemaking must be completed within 18 months after the Commission submits its congressional report, creating a total implementation window of approximately two and a half years from enactment. Notably, the bill explicitly exempts the rulemaking process from the Paperwork Reduction Act under §3(b)(3), streamlining the regulatory development process. Under §3(c), any violation of regulations issued pursuant to this bill is treated as a violation of a rule defining an unfair or deceptive act or practice under Section 18(a)(1)(B) of the Federal Trade Commission Act, triggering the full suite of FTC enforcement authorities.

Legal References

• Federal Trade Commission Act, 15 U.S.C. § 41 et seq.
• Federal Trade Commission Act § 18(a)(1)(B)
• Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 350a(h)(1)
• 5 U.S.C. § 553 (Administrative Procedure Act notice-and-comment rulemaking)
• Paperwork Reduction Act, 44 U.S.C. Subchapter I of Chapter 35

Implementation

The Federal Trade Commission bears sole responsibility for implementing this legislation. The implementation proceeds in two sequential phases governed by firm statutory deadlines. In the first phase, the FTC must complete its investigation and submit a report to Congress within one year of enactment. In the second phase, the Commission must finalize regulations within 18 months of submitting that report. The rulemaking must follow standard notice-and-comment procedures under the Administrative Procedure Act, though it is exempted from Paperwork Reduction Act requirements, which removes one layer of administrative review that could otherwise delay the process. Enforcement of the resulting regulations is integrated directly into the existing FTC enforcement architecture — the Commission enforces violations as though all applicable provisions of the Federal Trade Commission Act were incorporated into this legislation. This means the FTC can pursue civil penalties, injunctive relief, and other remedies available under the FTC Act against manufacturers or importers found to be in violation. No new enforcement mechanism or separate agency structure is created; the bill leverages the FTC's existing institutional capacity and legal authority.

Legal References

• Federal Trade Commission Act, 15 U.S.C. § 41 et seq.
• 5 U.S.C. § 553
• 44 U.S.C. Subchapter I of Chapter 35 (Paperwork Reduction Act)

Impact

The primary beneficiaries of this legislation are preterm infants and their families, who will gain stronger protections against misleading marketing that could lead to uninformed nutritional decisions with serious health consequences. Preterm infants face unique and elevated health risks compared to full-term infants, and the formula and fortifiers used in their care carry specific risk profiles that, if obscured through deceptive marketing, could result in harm. By requiring full disclosure of health risk information in advertising and marketing materials, the bill ensures that healthcare providers and families receive complete information at the point of product promotion — not merely at the point of labeling on the product itself. The administrative burden falls on the FTC, which must dedicate investigative and rulemaking resources over a multi-year period, and on manufacturers and importers of preterm infant formula, who will face new compliance obligations once regulations are finalized. The bill does not include an explicit appropriations provision, meaning the FTC must absorb implementation costs within existing budgetary authority. The long-term expected outcome is a marketplace where preterm infant formula advertising accurately reflects known health risks, reducing the potential for consumer deception in a high-stakes medical context. No sunset provision is included, making the resulting regulations permanent unless subsequently amended or repealed.

Key Points

• Preterm infants and their families are the direct beneficiaries of enhanced disclosure requirements
• Manufacturers and importers of preterm infant formula face new compliance obligations
• The FTC bears administrative costs with no dedicated appropriation
• No sunset provision — resulting regulations are permanent
• Protections extend to marketing materials beyond product labeling, closing a potential gap in existing disclosure requirements

Legal Framework

The bill operates squarely within the FTC's existing statutory authority under the Federal Trade Commission Act, which grants the Commission broad power to prohibit unfair or deceptive acts or practices in commerce. By anchoring violations of the new regulations to Section 18(a)(1)(B) of the FTC Act, the bill ensures that the full penalty and enforcement framework of that statute applies, including civil monetary penalties for knowing violations. The definitional scope of 'preterm infant formula' is tied to the Federal Food, Drug, and Cosmetic Act at 21 U.S.C. § 350a(h)(1), creating a cross-statutory definitional link that aligns the FTC's regulatory jurisdiction with the FDA's existing product classification framework. The rulemaking process is governed by the notice-and-comment requirements of 5 U.S.C. § 553, ensuring procedural regularity and public participation, while the explicit Paperwork Reduction Act exemption under §3(b)(3) removes a potential administrative bottleneck. The bill does not contain an express preemption clause, meaning state consumer protection laws addressing similar conduct are not displaced. There is no judicial review provision specific to this legislation, so challenges to FTC rules promulgated under this authority would proceed under the standard framework of the Administrative Procedure Act.

Legal References

• Federal Trade Commission Act, 15 U.S.C. § 41 et seq.
• Federal Trade Commission Act § 18(a)(1)(B)
• Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 350a(h)(1)
• Administrative Procedure Act, 5 U.S.C. § 553
• Paperwork Reduction Act, 44 U.S.C. Subchapter I of Chapter 35
• U.S. Constitution, Article I (Commerce Clause basis for FTC authority)

Critical Issues

Several implementation challenges and potential legal issues warrant attention. First, the bill does not appropriate dedicated funding for the FTC's investigation or rulemaking activities, which could slow implementation if the Commission's existing resources are constrained. The multi-year timeline — up to two and a half years from enactment before regulations take effect — means that potentially harmful marketing practices may continue unaddressed for a significant period. Second, the definitional boundary between 'preterm infant formula' and standard infant formula may create compliance ambiguity for manufacturers whose products are marketed to both populations, potentially leading to litigation over the scope of the regulations. Third, the absence of an express preemption clause, while preserving state authority, could result in a patchwork of overlapping state and federal requirements that increases compliance complexity for manufacturers operating nationally. Fourth, industry opponents may challenge the regulations on First Amendment commercial speech grounds, arguing that compelled disclosure requirements in advertising materials must satisfy the standard established in Zauderer v. Office of Disciplinary Counsel and its progeny, which could constrain the FTC's regulatory design choices. Fifth, the bill's reliance on the FTC's Section 18 rulemaking authority — which requires a substantial evidentiary record — means the investigation phase is not merely procedural but legally foundational; an inadequate investigative record could expose resulting regulations to successful administrative challenge. Finally, the July 27, 2026 date referenced in the bill's metadata suggests a potential legislative deadline or expiration consideration that could affect the bill's operative force if not enacted before that date.

Key Points

• No dedicated appropriation creates resource uncertainty for FTC implementation
• Two-and-a-half-year implementation window leaves a regulatory gap during which deceptive practices may continue
• Definitional ambiguity between preterm and standard infant formula may generate compliance and litigation uncertainty
• Absence of preemption clause risks conflicting state and federal regulatory requirements
• First Amendment commercial speech challenges under Zauderer doctrine could constrain regulatory design
• Adequacy of the investigative record is legally foundational to the validity of resulting Section 18 regulations

Legal References

• Zauderer v. Office of Disciplinary Counsel, 471 U.S. 626 (1985)
• Federal Trade Commission Act § 18(a)(1)(B)
• Administrative Procedure Act, 5 U.S.C. § 706 (judicial review of agency action)